Gujarat Themis Biosyn
358.47
-1.47(-0.41%)
Market Cap₹3,906.08 Cr
PE Ratio82.06
IndustryHealthcare
Company Performance:
1D-0.41%
1M+35.60%
6M-20.77%
1Y+20.86%
5Y+47.24%
View Company Insightsright
More news about Gujarat Themis Biosyn
05Feb 26
Gujarat Themis Biosyn Q3FY26 Results Show Strong Performance with Strategic Expansion Plans
Gujarat Themis Biosyn delivered strong Q3FY26 performance with revenue growth of 9.74% to ₹434 crores and EBITDA margin improvement to 49.13%. The company completed its new fermentation facility expansion, appointed Krupesh Patel as new CFO, and is implementing strategic initiatives including hybrid renewable power project and forward integration into API production.
 no imag found
14Jan 26
Gujarat Themis Biosyn: Themis Medicare pledges 3.5 lakh shares to Jio Credit Limited
Themis Medicare Limited pledged 3,50,000 equity shares of Gujarat Themis Biosyn Limited to Jio Credit Limited on January 12, 2026, against a ₹10 crore borrowing facility. The pledge aims to repay high-interest loans and reduce finance costs. Post-transaction, Themis Medicare's total encumbered shareholding increased to 12,70,000 shares (1.38% of total capital).
 no imag found
07Jan 26
Gujarat Themis Biosyn Issues Postal Ballot for Director Appointment, Reports Strong Q2 Growth
Gujarat Themis Biosyn Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Rajneesh Anand as Non-Executive Non-Independent Director for a five-year term with professional fees of ₹10 lakhs per month. The company continues to demonstrate strong financial performance with Q2 net profit growing 44.44% year-on-year to ₹442.64 crores, alongside successful completion of fermentation capacity expansion that more than doubled production capabilities from 450 KL to 990 KL.
 no imag found
03Jan 26
Themis Medicare pledges 9.2 lakh shares of Gujarat Themis Biosyn for ₹10 crore facility
Themis Medicare Limited pledged 9,20,000 equity shares of Gujarat Themis Biosyn Limited on December 30, 2025, against a ₹10 crore facility from Jio Credit Limited. The pledge, disclosed under SEBI regulations, aims to repay high-interest loans and reduce finance costs. Post-pledge, Themis Medicare's encumbered shareholding stands at 9,20,000 shares (3.64% of pledged shares, 0.84% of total capital) while maintaining its overall 23.19% stake in Gujarat Themis Biosyn.
 no imag found
18Oct 25
Gujarat Themis Biosyn Doubles Fermentation Capacity with New Plant Commencement
Gujarat Themis Biosyn Limited (GTBL) has begun commercial production at its expanded Fermentation Block in Vapi, Gujarat. The new facility, operational from October 18, 2025, produces Rifamycin-S and Rifamycin-O. This expansion has increased GTBL's fermentation capacity from 450.00 KL to 990.00 KL, marking a 120% increase. The company aims to capitalize on growth opportunities in the fermentation segment with this enhanced capacity, enabling increased output and product diversification.
 no imag found
01Aug 25
Gujarat Themis Biosyn Reports Q1 FY2026 Results, Announces Board Changes and New API Plant
Gujarat Themis Biosyn reported Q1 FY2026 total income of ₹3,614.72 lakh and net profit of ₹926.16 lakh. The company set September 5, 2025, as the dividend record date. Board changes include appointment of Nihar Parikh as Additional Non-Executive Independent Director and cessation of Siddharth Kusumgar's term. A new API plant in Vapi, Gujarat commenced operations on May 1, 2025, aimed at strengthening the company's position in domestic and export markets.
 no imag found
01Aug 25
Gujarat Themis Biosyn Reports Q1 Results, Appoints New Director, and Commences API Plant Operations
Gujarat Themis Biosyn reported Q1 total income of ₹3,614.72 crore, down 8.14% YoY, with net profit after tax at ₹926.16 crore, a 30.03% decrease. The company appointed Mr. Nihar Parikh as Additional Non-Executive Independent Director and announced the start of commercial production at a new API plant in Vapi, Gujarat. September 5 set as record date for dividend eligibility.
 no imag found
01Aug 25
Gujarat Themis Biosyn Reports Q1 Results, Announces Board Changes and New API Plant
Gujarat Themis Biosyn Limited reported Q1 FY2025-26 results with total income of ₹3,614.72 lakhs and net profit of ₹926.16 lakhs, showing a decline from the previous year. The company set September 5 as the dividend record date. Board changes include the appointment of Mr. Nihar Parikh as an Additional Non-Executive Independent Director and the upcoming cessation of Mr. Siddharth Kusumgar's term. A new API plant in Vapi, Gujarat commenced operations on May 1, aimed at strengthening the company's position in export markets. The company has decided to focus on its core business of fermentation-based pharmaceutical intermediates and APIs, abandoning the previously planned merger with Themis Medicare Limited.
 no imag found
01Aug 25
Gujarat Themis Biosyn Reports Q1 Decline and Board Reshuffles
Gujarat Themis Biosyn Limited (GTBL) reported a 31.06% decrease in net profit to ₹91.00 crore and a 7.71% decline in revenue to ₹359.00 crore for Q1. The company appointed Mr. Nihar Parikh as an Additional Non-Executive Independent Director and announced the upcoming cessation of Mr. Siddharth Kusumgar's term. GTBL decided to focus on its core business of fermentation-based pharmaceutical intermediates and APIs, abandoning the proposed merger with Themis Medicare Limited. The company also began commercial production at its new API plant in Vapi, Gujarat.
 no imag found
20May 25
Gujarat Themis Biosyn Reports Decline in Q4 Financial Performance
Gujarat Themis Biosyn's Q4 results show a decline in key financial metrics. Revenue decreased by 10.1% to ₹377.4 crore, while net profit fell 25% to ₹120 crore compared to the previous year. EBITDA dropped 23.3% to ₹160.4 crore, with the EBITDA margin contracting to 42.5% from 49.82%. The company faces challenges across revenue, profitability, and operational efficiency.
 no imag found
06May 25
Gujarat Themis Biosyn Launches Commercial Production at New API Plant
Gujarat Themis Biosyn Ltd (GTBL) has commenced commercial production at its new Active Pharmaceutical Ingredient (API) plant in Gujarat. This strategic move aims to enhance the company's manufacturing capabilities and expand its market reach. The new facility is expected to strengthen GTBL's forward integration initiatives, potentially improving profit margins and supply chain control. The company is focusing on reinforcing its position in key export markets, particularly the United States and Europe. This expansion signifies GTBL's commitment to growth and innovation in the pharmaceutical sector, positioning it to meet increasing global demand for high-quality APIs.
 no imag found
Gujarat Themis Biosyn
358.47
-1.47
(-0.41%)
1 Year Returns:+20.86%
Industry Peers
Sun Pharmaceutical
1,733.50
(+6.98%)
Divis Laboratories
6,477.00
(+1.82%)
Torrent Pharmaceuticals
4,219.80
(+2.49%)
Dr Reddys Laboratories
1,334.50
(+1.32%)
Cipla
1,317.20
(+1.71%)
Lupin
2,324.50
(+1.24%)
Zydus Life Science
939.65
(+1.32%)
Mankind Pharma
2,268.70
(+0.06%)
Aurobindo Pharma
1,416.70
(+0.21%)
Glenmark Pharmaceuticals
2,325.10
(+1.11%)